item management s discussion and analysis of financial condition and results of operations overview statements made in this form k  other than those concerning historical information  should be considered forward looking and subject to various risks and uncertainties 
such forward looking statements are made based on management s belief as well as assumptions made by  and information currently available to  management pursuant to the safe harbor provisions of the private securities litigation reform act of the company s actual results may differ materially from the results anticipated in these forward looking statements as a result of a variety of factors  including those identified in business and elsewhere in this annual report on form k for the fiscal year ended june  since its inception  the company has been engaged primarily in the research and development and  more recently  the commercialization of proprietary products relating to the detection  diagnosis and treatment of cancer and infectious diseases 
the company has incurred significant operating losses since its formation in and has not earned a profit since its inception 
these operating losses and failure to be profitable have been due mainly to the significant amount of money that the company has had to spend on research and development 
as of june   the company had an accumulated deficit of approximately  the company expects to continue to experience operating losses until such time  if at all  that it is able to generate sufficient revenues from sales of cea scan r  leukoscan r and its other potential products 
on june   the us food and drug administration fda licensed cea scan for use with other standard diagnostic modalities for the detection of recurrent and or metastatic colorectal cancer 
on october   the european commission granted marketing authorization for use of the product in the countries comprising the european union for the same indication 
on september   the company received a notice of compliance from the health protection branch permitting it to market cea scan in canada for colorectal cancer for recurrent and metastatic colorectal cancer 
on february   the company was granted regulatory approval by the european commission to market leukoscan r  an in vivo infectious disease diagnostic imaging product  in all countries which are members of the european union  for the detection and diagnosis of osteomyelitis bone infection in long bones and in diabetic foot ulcer patients 
on december   the company filed a biologics license application  or bla for leukoscan with the fda for the same indication approved in europe  plus an additional indication for the diagnosis of acute  atypical appendicitis 
as part of the review process  the company is in discussions with the fda to address its comments regarding the adequacy of the company s data to support final approval for these indications 
consistent with the compan s decision to focus primarily on cancer therapeutic products  on april   the company withdrew the cea scan breast cancer imaging application submitted on january  to the european medicines evaluation agency emea 
a new drug submission for leukoscan for the same indications as in the us was filed with the hpb in canada on march  the company also has decided not to continue pursuing the broadening of its approval for leukoscan in europe to include the acute  atypical appendicitis indication  but has instead published its phase iii efficacy data 
cea scan and leukoscan are the only products which the company is currently licensed to market and sell 
to date  the company has received only limited revenues from the sale of these products 
there can be no assurance that these products will achieve market acceptance or generate significant sales 
unless the company receives substantial revenues from these products  future revenues will be dependent in large part upon its receiving payments from corporate partners under licensing and research agreements or from government grants 
however  there can be no assurance that the company will receive such payments in a timely manner  or at all 
the company is also engaged in developing other biopharmaceutical products  which are in various stages of development and clinical testing 
the company has developed and filed an investigational new drug application ind for two other in vivo cancer imaging products afp scan r for the detection and diagnosis of liver and germ cell cancers  currently in phase ii clinical trials  and lymphoscan tm for diagnosis and staging of non hodgkin s lymphomas  currently in phase iii clinical trials see products and projects in development 
results of operations fiscal year compared to fiscal year revenues for fiscal year were  as compared to  in fiscal year  representing a decrease of  the product sales for fiscal year were  as compared to  in fiscal year  representing a decrease of  mainly due to the reorganization of the us and european sales forces  which occurred in april research and development revenue for fiscal year decreased by  as compared to fiscal interest and other income for fiscal year increased by  interest income increased by  due to more cash available for investments as a result of infusions of private equity capital during fiscal other income decreased by  primarily due to the receipt of  in december  in final settlement of all claims between the company and mallinckrodt  inc and its affiliate under certain prior distribution agreements  which were terminated in april total operating expenses for fiscal year were  as compared to  in fiscal year  representing a decrease of  research and development costs decreased by  as compared to fiscal year  primarily due to the company s restructuring efforts in fiscal and lower cost associated with reduced patient enrollment for clinical trials 
cost of goods sold for fiscal year increased by  as compared to fiscal year included in the cost of goods sold for fiscal year is a charge of approximately  due to expiration of vials of cea scan previously manufactured and capitalized which was partially offset by the effect of decreased product revenues 
in addition  cost of goods sold for fiscal year and does not include production costs of certain products sold since such costs were previously expensed prior to receiving product approval 
sales and marketing expenses for fiscal year were  as compared to  in fiscal year  representing a decrease of  primarily due to the company wide reorganization restructuring 
general and administrative costs for fiscal year increased by  as compared to fiscal year  primarily due to the recognition of an expense of  associated with warrants issued to a financial advisor in december and  awarded to executives as a bonus in fiscal year in recognition for their efforts with the company s equity financings see note to consolidated financial statements 
net loss allocable to common shareholders for fiscal year was  or per share  as compared to  or per share  in fiscal year the lower net loss of  in as compared to primarily resulted from lower operating expenses  partially offset by lower revenues  as discussed above  and the accretion of preferred stock dividends on the series f preferred stock issued in december see liquidity and capital resources 
in addition  the net loss allocable to common shareholders per share for fiscal was positively impacted by the higher weighted average number of shares outstanding during such period as compared to fiscal  which increase was principally due to the conversion of the company s series f preferred stock and the issuance of common stock pursuant to the company s equity financings see note to consolidated financial statements 
fiscal year compared to fiscal year revenues for fiscal year were  as compared to  in fiscal year  representing a decrease of  the product sales for fiscal year were  as compared to  in fiscal year  representing an increase of  the increase in product sales is mainly due to increased market acceptance of cea scan and leukoscan 
research and development revenue for fiscal year decreased by  as compared to fiscal  primarily due to the recognition in fiscal year  of previously deferred revenue received from pharmacia inc pharmacia in fiscal year and a decrease in grant revenue of  interest and other income for fiscal year decreased by  interest income decreased by  due to less cash available for investments 
other income decreased by  primarily due to the receipt  in november  of an arbitration award of  including interest from its dispute with pharmacia 
the decrease in other income was offset in part by the receipt and recognition in fiscal year of  in final settlement of all claims between the company and mallinckrodt  inc and its affiliate under the prior distribution agreements  which were terminated in april see liquidity and capital resources 
total operating expenses for fiscal year were  as compared to  in fiscal year  representing a decrease of  research and development costs decreased by  as compared to fiscal year  primarily due to a decrease in the level of expenditures required to obtain validation of the company s manufacturing facility and lower cost associated with reduced patient enrollment for clinical trials 
cost of goods sold for fiscal year increased by  as compared to fiscal year  mainly due to increased product sales 
however  the decrease in cost of goods sold as a percentage of product sales reflects the benefit of product sales from inventory which was previously expensed by the company prior to receiving product approval 
sales and marketing expenses for fiscal year were  as compared to  in fiscal year  representing an increase of  primarily due to an increase in personnel associated with the company s full time oncology sales force in us and increased operating expenses for immunomedics europe  which increased  by  as compared to fiscal year general and administrative costs for fiscal year decreased by  as compared to fiscal year  primarily due to reduced legal costs as a result of the conclusion of the pharmacia arbitration  which was settled in november net loss allocable to common shareholders for fiscal year was  or per share  as compared to a net loss of  or per share  in fiscal year the lower net loss of  in as compared to primarily resulted from lower operating expenses  partially offset by slightly lower revenues  as discussed above and the accretion of preferred stock dividends on the series f preferred stock issued in december see liquidity and capital resources 
in addition  the net loss per share for fiscal was positively impacted by the higher weighted average number of shares outstanding during such period as compared to fiscal  which increase was principally due to the conversion of the company s series d preferred stock which was fully converted as of june  and the issuance of common stock pursuant to the company s structured equity line flexible financing agreement see note to consolidated financial statements 
liquidity and capital resources at june   the company had working capital of  representing an increase of  from june  the company has long term obligations of  and certain other lease obligations see note of notes to consolidated financial statements 
the net increase in working capital resulted principally from the company s december and february private placements of equity securities partially offset by the net loss allocable to common shareholders during fiscal year of  redemption of preferred stock and capital expenditures 
on december   the company completed a private placement of  shares of series f convertible preferred stock the series f stock to several investors and received net proceeds of  each share of series f stock had an initial stated value of  which increased at the rate of per annum 
as of december   shares of the series f stock had been converted into  shares of common stock 
the remaining shares of series f stock were repurchased  in accordance with the terms of the series f stock  by the company on that date from the holders at a price equal to of initial the stated value of  per share of series f stock 
on december   the company issued a warrant covering  shares of its common stock at an exercise price of per share 
the warrants were issued to induce a financial advisor to enter into a financial advisory agreement with the company 
in accordance with eitf issue no  accounting for equity instruments that are issued to other than employees for acquiring  or in conjunction with selling  goods or services and other relative accounting literature  the company is required to measure the expense associated with the warrants at each reporting date and recognize the appropriate portion of the expense at the end of each reporting period until the measurement date is reached december  in this transaction 
as a result  the company recognized a proportionate share of the general and administrative expense of approximately  for the fiscal year ended june  based on the estimated value of the warrants as of that date 
on december   the company completed a private placement of  shares of its common stock at per share to several investors and received net proceeds of  substantially all of the net proceeds were used to redeem the series f stock as described above 
on february   the company completed another private placement of  shares of its common stock at per share to several investors and received net proceeds of  net proceeds from this placement will be used as required to fund the continued operations of the company 
on october   the company entered into an equipment financing agreement with the new england capital corporation  pursuant to which the company has received  to be repaid over a month period 
the proceeds of such financing were used to exercise the early purchase options for equipment previously leased through a master lease agreement 
the financing is secured by various used equipment and an irrevocable letter of credit in the amount of  the letter of credit is collateralized by a cash deposit of an equivalent amount 
the company s liquid asset position  as measured by its cash  cash equivalents and marketable securities  was  at june   representing an increase of  from june  this increase was primarily attributable to the private placements that occurred in december and february partially offset by the funding of operating expenses 
it is anticipated that working capital and cash  cash equivalents  and marketable securities will decrease during fiscal year as a result of planned operating expenses and capital expenditures  offset in part by projected revenues from product sales in the u 
s 
and europe 
however  there can be no assurance  as to the amount of revenues  if any  these products will provide 
in april  the company implemented a cost reduction program  which the company anticipated saving approximately million during the months ending march  primarily due to the restructuring  the company has realized savings of approximately million 
on may   the company gave notice to its landlord that it desired to exercise its right to purchase the facilities  which the company presently leases at american road  morris plains  new jersey see properties 
the purchase price under the lease is approximately million 
the company plans to seek mortgage financing with respect to this purchase 
if such financing is not available to the company on acceptable terms prior to the closing  the company would expect to fund the purchase price on an interim basis from its own capital resources and would then likely seek to mortgage the acquired premises 
no assurances can be given that the company will be able to secure favorable financing either before or after the purchase of these facilities 
to date  the company has not generated positive cash flow from operations 
the company believes that its existing working capital should be sufficient to meet its capital and liquidity requirements for the foreseeable future 
this expectation represents a forward looking statement under the private securities litigation reform act of actual results could differ materially from the company s expectation as a result of a number of risks and uncertainties  including the risks described under business presented elsewhere herein 
the company s working capital and working capital requirements are affected by numerous factors and there is no assurance that such factors will not have a negative impact on the company s liquidity 
principal among these are the success of its product commercialization and selling products  the technological advantages and pricing of the company s products  the impact of the regulatory requirements applicable to the company and access to capital markets that can provide the company with the resources when necessary to fund its strategic priorities 
unless there is a significant increase in product revenues  the company will require additional financial resources after it utilizes its current liquid assets in order for it to continue its projected levels of research and development and clinical trials of its proposed products and regulatory filings for new indications of existing products 
there can no assurance that any additional financing will be available to the company at all or on terms it finds acceptable or that the terms of such financing will not cause substantial dilution to existing stockholders 
the company intends to supplement its financial resources from time to time as market conditions permit through additional financing and through collaborative marketing and distribution agreements 
the company continues to evaluate various programs to raise additional capital and to seek additional revenues from the licensing of its proprietary technology 
at the present time  the company is unable to determine whether any of these future activities will be successful and  if so  the terms and timing of any definitive agreements 
recently issued accounting standards in december  the staff of the securities and exchange commission issued staff accounting bulletin or sab no 
 revenue recognition in financial statements 
sab no 
summarizes certain of the staff s views in applying generally accepted accounting principles to revenue recognition in financial statements  including the recognition of non refundable fees received upon entering into arrangements 
this sab  as amended  must be adopted no later than the fourth quarter of fiscal years beginning after december  the company is in the process of evaluating this sab and the effect it will have on its consolidated financial statements and current revenue recognition policy 
in june  statement of financial accounting standard sfas no 
 accounting for derivative instruments and hedging activities  was issued and is effective for all fiscal quarters of all fiscal years beginning after june  sfas no 
 as amended by sfas no 
 requires derivative instruments to be recognized as assets and liabilities in the company s balance sheet and be recorded at fair value 
the company is currently not party to any derivative instruments 
any future transactions involving derivative instruments will be evaluated based on sfas no 
the company does not expect the adoption of sfas no 
to have a material impact on its financial position  results of operations or cash flows 
item a quantitative and qualitative disclosures about market risk the following discussion about the company s exposure to market risk of financial instruments contains forward looking statements 
actual results may differ materially from those described due to a number of factors  including uncertainties associated with general economic conditions and conditions impacting the company s industry 
the company s holdings of financial instruments are comprised primarily of corporate debt 
all such instruments are classified as securities available for sale 
the company does not invest in portfolio equity securities or commodities or use financial derivatives for trading purposes 
the company s debt security portfolio represents funds held temporarily pending use in its business and operations 
the company manages these funds accordingly 
the company seeks reasonable assuredness of the safety of principal and market liquidity by investing in rated fixed income securities while at the same time seeking to achieve a favorable rate or return 
the company s market risk exposure consists principally of exposure to changes in interest rates 
the company s holdings also are exposed to the risks of changes in the credit quality of issuers 
the company typically invests in the shorter end of the maturity spectrum  and at june  most of the company s holdings were in instruments maturing in less than months 

